According to CNBC:

The new Alzheimer’s treatment Leqembi will cost an estimated $26,500 per year, according to Eisai, the company that led the drug’s development.
Most seniors who are eligible for Leqembi will have to pay out of pocket because Medicare has limited coverage to people participating in studies approved by the federal government.
“Without Medicare coverage, this drug is pretty much unaffordable,” said Tricia Neuman, a Medicare expert at the Kaiser Family Foundation.

The Black Financial Channel is a news and business channel designed specifically for the African American community. We give daily financial updates on stock markets, investing and other related topics that appear in financial news.

The Black Financial Channel is sponsored by The Black Business School. To join The Black Business School and get started for free, please visit http://TheBlackBusinessSchool.com.

You can enroll in Dr Watkins’ Stock Market Investing class by visiting http://TheBlackStockMarketProgram.com.

source